Designation of Teduglutide (Revestive) as an orphan drug - Shire Australia Pty Ltd.

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate therapeutic goods, including medicines, medical devices, and blood and tissues, to ensure they meet safety, quality, and efficacy standards. This Act was introduced to address the need for a comprehensive regulatory framework that would protect public health by controlling the supply, advertising, and representation of therapeutic goods within Australia. One of the mechanisms under this Act is the designation of orphan drugs, which are intended for the treatment of rare diseases or conditions. In this context, the designation of teduglutide (REVESTIVE) as an orphan drug on 13 June 2017 by Dr Anthony Gill, the Delegate of the Secretary, aims to facilitate the development and availability of treatments for paediatric patients with Short Bowel Syndrome who are dependent on parenteral support, thereby addressing a significant therapeutic need for a small patient population.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA), designates teduglutide (REVESTIVE) as an orphan drug specifically for the treatment of paediatric patients with Short Bowel Syndrome who rely on parenteral support. This legislative action pertains to the pharmaceutical product manufactured by Shire Australia Pty Ltd and applies to the therapeutic application of teduglutide in the designated patient group. The scope of this designation under the Therapeutic Goods Regulations 1990 is confined to the specified condition and patient population, aiming to address the unmet medical needs of this rare paediatric condition. The orphan drug designation is intended to facilitate the development and availability of treatments for rare diseases or conditions that would otherwise lack sufficient commercial incentive for research and development. The geographic reach of this legislation is national, as it operates within the Australian regulatory framework overseen by the Commonwealth of Australia. There are no exclusions or exemptions stated within this particular designation, and the application of the Act extends through the subordinate instruments of the Therapeutic Goods Regulations 1990.

Key Provisions

The Therapeutic Goods Act 1989 (section 16J) allows the Therapeutic Goods Administration (TGA) to designate certain therapeutic goods as orphan drugs. This designation is particularly significant for drugs intended for rare conditions, ensuring they receive necessary support and attention. In this case, teduglutide (REVESTIVE) has been designated as an orphan drug (section 16J) for treating paediatric patients with Short Bowel Syndrome who rely on parenteral support, effective from 13 June 2017. The specific formulation designated is the powder for solution for injection, and Shire Australia Pty Ltd is the sponsor of this therapeutic good. The obligations imposed by this designation include ensuring that teduglutide (REVESTIVE) meets all regulatory requirements for orphan drugs, including quality, safety, and efficacy standards. The sponsor, Shire Australia Pty Ltd, must also ensure that the drug is manufactured and supplied in compliance with the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This involves rigorous adherence to Good Manufacturing Practice (GMP) standards and timely submission of any required data or information to the TGA. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in severe penalties. Offences may include manufacturing, supplying, or advertising therapeutic goods that do not meet the required standards, which can lead to both civil and criminal consequences. Under the Act, individuals and companies can face substantial fines, with the maximum penalty for corporations potentially reaching up to $5.5 million under certain provisions. Additionally, individuals involved in the breach may face imprisonment, reflecting the seriousness of non-compliance with these health and safety regulations.